Loading
A phase 3 trial of HPV quadrivalent vaccine in cervical cancer and vulvar cancer, run by Shanghai Bovax Biotechnology Co., Ltd., now recruiting.
Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females is a phase 3 interventional study registered as NCT04422366 by Shanghai Bovax Biotechnology Co., Ltd., with 8000 participants planned, started 2020-04-28 and due to reach its primary completion in 2027-09-15. Interventions recorded: 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha), GARDASIL®. Conditions listed: Cervical Cancer, Vulvar Cancer, Vaginal Cancer, CIN1. No results are recorded here; the registry entry is the source.
Shares Shanghai Bovax Biotechnology, Vaginal squamous cell carcinoma (HPV-associated), Vaginal cancer, Cervical cancer.
Shares Shanghai Bovax Biotechnology, HPV quadrivalent vaccine (types 6, 11, 16 and 18), Cancer interception vaccines, HPV & HBV vaccination.
Shares HPV quadrivalent vaccine (types 6, 11, 16 and 18), Cancer interception vaccines, HPV & HBV vaccination, Cervical cancer.
Shares Vaginal squamous cell carcinoma (HPV-associated), Vaginal cancer.
Shares Vaginal cancer, Vulvar cancer, Cervical cancer.
Shares HPV quadrivalent vaccine (types 6, 11, 16 and 18), HPV-associated vulvar squamous cell carcinoma, Vaginal squamous cell carcinoma (HPV-associated), Vaginal cancer.
Shares HPV-associated vulvar squamous cell carcinoma, Vulvar cancer.
Shares HPV-associated vulvar squamous cell carcinoma, Vulvar cancer.